Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
957 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07416513 | Digital Solutions for bEtter cAre(ALTHEA) | recruiting | N/A | 200 | European Institute of OncologyOTHER | 5 | Feb 18, 2026 | clinicaltrials |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | recruiting | — | 680 | argenxINDUSTRY | 6 | Feb 17, 2026 | clinicaltrials |
| NCT07337876 | Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy(MARS) | recruiting | Phase 2 | 100 | University Hospital TuebingenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407465 | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA) | recruiting | Phase 2 | 42 | Gruppo Oncologico del Nord-OvestOTHER | 4 | Feb 17, 2026 | clinicaltrials |
| NCT07410637 | Impact of Thyroid Hormones on Human Glucose and Energy Metabolism | recruiting | N/A | 60 | University of UlmOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05914961 | Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer | recruiting | — | 225 | University Hospital TuebingenOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05878314 | Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer | recruiting | — | 504 | University Hospital TuebingenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05914974 | Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies | recruiting | — | 120 | University Hospital TuebingenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen(CHONQUER) | recruiting | Phase 3 | 136 | Servier Bio-Innovation LLCINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT04122872 | GISAR German Interdisciplinary Sarcoma Registry(GISAR) | recruiting | — | 9,000 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05366218 | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia(Anti-CD19-ALL) | recruiting | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07270991 | Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma(FRUQUITAS) | recruiting | Phase 3 | 324 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Feb 5, 2026 | clinicaltrials |
| NCT07365930 | NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy(NISTIPS) | recruiting | — | 350 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT04495088 | Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 3 | 550 | Ralf HofheinzOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02338167 | Praegnant Breast Cancer: Early/Advanced/Metastatic(PRAEGNANT) | recruiting | — | 13,500 | University Hospital TuebingenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05843877 | Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula(XandTX) | recruiting | Phase 3 | 32 | Technische Universität DresdenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04290806 | Registry Platform Gastric/Esophageal Cancer (SAPHIR)(SAPHIR) | recruiting | — | 1,900 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05129969 | Registry Platform Ovarian and Endometrial Cancer(SMARAGD) | recruiting | — | 1,975 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05652569 | CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer(CATCH) | recruiting | — | 5,000 | German Cancer Research CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06840119 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | recruiting | Phase 1 / Phase 2 | 600 | Immunocore LtdINDUSTRY | 6 | Jan 28, 2026 | clinicaltrials |
| NCT07322796 | Smoking Cessation Before Bronchoscopy or CT-guided Puncture | recruiting | — | 25 | RWTH Aachen UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06810609 | Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC(InDuRanS) | recruiting | Phase 2 | 176 | University Hospital, BonnOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT07044427 | Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients(Myfall) | recruiting | N/A | 60 | University Hospital HeidelbergOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04067167 | Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases(FREEDOM) | recruiting | N/A | 100 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07231458 | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | recruiting | Phase 1 | 27 | Abalos Therapeutics GmbHINDUSTRY | 2 | Jan 16, 2026 | clinicaltrials |
| NCT04271579 | Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)(ProsTone) | recruiting | N/A | 397 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05671458 | Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors(NAVIGATORR) | recruiting | N/A | 60 | Juergen DebusOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT07129551 | Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery(NICE-PSMA) | recruiting | N/A | 102 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06743035 | Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly(ROPE) | recruiting | — | 200 | iOMEDICO AGINDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07240662 | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma(VIOLETA) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326111 | A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese(PERIODS) | recruiting | Phase 4 | 198 | University of BonnOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06282016 | Risk Factors for Neuroendocrine Neoplasms | recruiting | — | 14,250 | Bavarian Cancer RegistryOTHER_GOV | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01252485 | Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project(AMLSG BiO) | recruiting | — | 50,000 | University of UlmOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT02986516 | Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease(SACRO) | recruiting | N/A | 100 | Italian Sarcoma GroupNETWORK | 10 | Jan 2, 2026 | clinicaltrials |
| NCT07313878 | Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy(HEALED) | recruiting | N/A | 30 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07313943 | PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE(HL PAX5- 2025) | recruiting | — | 60 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 2 | Jan 2, 2026 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT07312760 | Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU) | recruiting | N/A | 160 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05695508 | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5(HD10/DSMMXX) | recruiting | Phase 2 | 160 | University of Heidelberg Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06722183 | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities(FUTURE) | recruiting | Phase 2 | 33 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials